Trial · NCT04745728
Different Immunosuppressive Treatment in iMN
NCT04745728, Phase 3, Recruiting, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Different Immunosuppressive Treatment in iMN. Trials, record NCT04745728. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04745728
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Different Immunosuppressive Treatment in iMN
- NCT number
- NCT04745728
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Prednisone, Cyclophosphamide, Rituximab
- First posted
- 2021-02-09
- Last updated
- 2025-12-09
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | complete or partial remission on 24 month | 24 months | Complete remission is defined as urine protein \< 0.5g/24h and serum albumin≥ 3.5g/dl. Partial remission is defined as reduction in urine protein≥50% plus urine protein ≤3.5g/24h but \>0.5g/24h |
| Secondary | complete or partial remission on 6, 12 and 18 month | 6, 12 and 18 months | complete or partial remission on 6, 12 and 18 month |
| Secondary | complete remission on 6, 12, 18 and 24 month | 6, 12, 18 and 24 months | complete remission on 6, 12, 18 and 24 month |
| Secondary | time to complete or partial remission | from date of treatment until the date of first documented remission, up to 24 months | time to complete or partial remission |
| Secondary | change of estimated glomerular filtration rate (eGFR) | 24 months | change of estimated glomerular filtration rate (eGFR) from baseline |
| Secondary | serum creatinine increase ≥50 percent from baseline | 24 months | proportion of patients with increase of serum creatinine ≥50 percent from baseline |
| Secondary | rate of relapse | 12, 18, 24 months | proportion of patients with relapse. Relapse is defined as development of urine protein \>3.5g/24h following complete or partial remission. |
| Secondary | anti-PLA2R levels | baseline and 3, 6, 9, 12, 18, 24 months | Auto-antibody to the M-type phospholipase A2 receptor (PLA2R) |
| Secondary | CD19+ B cell count | baseline and 3, 6, 9, 12, 18, 24 months | CD19+ B cell count |
| Secondary | Adverse events | through the study completion until 24 months | Adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04745728
GET https://conductscience.org/api/trials/v1/NCT04745728/registered